crizanlizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5365 1690318-25-2

Description:

MoleculeDescription

Synonyms:

  • crizanlizumab
  • crizanlizumab-tmca
  • adavkeo
  • SEG101
  • SelG1
  • NVP-LXI262
Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands including P-selectin glycoprotein ligand 1. Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells, platelets, red blood cells, and leukocytes.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
12.50 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 28, 2020 EMA NOVARTIS EUROPHARM LIMITED
Nov. 15, 2019 FDA NOVARTIS PHARMS CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sickle cell anaemia with crisis 416.89 47.16 71 744 5932 63482275
Pain 152.58 47.16 101 714 740527 62747680
Acute chest syndrome 108.75 47.16 17 798 804 63487403
Back pain 92.06 47.16 51 764 264094 63224113
Infusion related reaction 76.19 47.16 44 771 245477 63242730

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sickle cell anaemia with crisis 393.01 59.88 64 406 3989 34952472
Pain 118.64 59.88 56 414 204619 34751842
Back pain 104.42 59.88 44 426 121745 34834716
Infusion related reaction 91.49 59.88 32 438 53025 34903436
Acute chest syndrome 79.03 59.88 13 457 814 34955647
Chest pain 70.61 59.88 34 436 126728 34829733

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sickle cell anaemia with crisis 420.07 46.58 74 903 7848 79735563
Pain 160.71 46.58 101 876 703701 79039710
Acute chest syndrome 140.41 46.58 23 954 1538 79741873
Back pain 135.37 46.58 68 909 304112 79439299
Infusion related reaction 127.97 46.58 60 917 230177 79513234
Chest pain 80.08 46.58 47 930 282257 79461154
Pain in extremity 66.64 46.58 46 931 364492 79378919

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B06AX01 BLOOD AND BLOOD FORMING ORGANS
OTHER HEMATOLOGICAL AGENTS
OTHER HEMATOLOGICAL AGENTS
Other hematological agents
FDA MoA N0000194031 P-Selectin Blockers
FDA EPC N0000194032 Selectin Blocker

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vaso-occlusive crisis in sickle cell disease indication 769167005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
P-selectin Adhesion INHIBITOR IC50 5.59 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEMBL4297734 ChEMBL_ID
D11480 KEGG_DRUG
C000614139 MESH_SUPPLEMENTAL_RECORD_UI
10550 IUPHAR_LIGAND_ID
DB15271 DRUGBANK_ID
018193 NDDF
830102002 SNOMEDCT_US
830160007 SNOMEDCT_US
4038967 VANDF
4038968 VANDF
C4524703 UMLSCUI
10316 INN_ID
2262279 RXNORM
37673 MMSL
37674 MMSL
d09436 MMSL
L7451S9126 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ADAKVEO HUMAN PRESCRIPTION DRUG LABEL 1 0078-0883 INJECTION 10 mg INTRAVENOUS BLA 30 sections
ADAKVEO HUMAN PRESCRIPTION DRUG LABEL 1 0078-0883 INJECTION 10 mg INTRAVENOUS BLA 30 sections
ADAKVEO HUMAN PRESCRIPTION DRUG LABEL 1 0078-0883 INJECTION 10 mg INTRAVENOUS BLA 30 sections